Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in <i>MDM</i> 2-Amplified Liposarcoma
Staging dedifferentiated liposarcoma based on the size of the dedifferentiated component better predicts the outcome.
Authors
- Haiming Tang (ORCID: https://orcid.org/0000-0001-7058-349X)
- Seth M. Pollack (ORCID: https://orcid.org/0000-0002-2466-0607)
- Madina Jh. SUKHANOVA (ORCID: https://orcid.org/0000-0002-1843-7038)
- Hao Wu (ORCID: https://orcid.org/0000-0002-8903-4658)
- Xinyan Lu (ORCID: https://orcid.org/0000-0002-4037-9284)
- Hari A. Deshpande (ORCID: https://orcid.org/0000-0003-0697-9355)
- Minghao Zhong (ORCID: https://orcid.org/0009-0001-4581-5399)
- Borislav A. Alexiev (ORCID: https://orcid.org/0000-0002-0262-2263)
- William B. Laskin (ORCID: https://orcid.org/0000-0003-3991-3993)
Institutions
- Northwestern University (US)
- University of Minnesota (US)
- Yale New Haven Hospital (US)
- Northwestern Memorial Hospital (US)
- Twin Cities Orthopedics (US)
- Smilow Cancer Hospital (US)
Publication Details
- Journal
- Archives of Pathology & Laboratory Medicine
- Published
- 2024-08-21
- DOI
- https://doi.org/10.5858/arpa.2024-0098-oa
- Citations
- 3
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26